PL377606A1 - Postaci dawkowane zawierające inhibitor CETP i inhibitor reduktazy HMG-CoA - Google Patents
Postaci dawkowane zawierające inhibitor CETP i inhibitor reduktazy HMG-CoAInfo
- Publication number
- PL377606A1 PL377606A1 PL377606A PL37760603A PL377606A1 PL 377606 A1 PL377606 A1 PL 377606A1 PL 377606 A PL377606 A PL 377606A PL 37760603 A PL37760603 A PL 37760603A PL 377606 A1 PL377606 A1 PL 377606A1
- Authority
- PL
- Poland
- Prior art keywords
- inhibitor
- hmg
- dosage forms
- coa reductase
- cetp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43534502P | 2002-12-20 | 2002-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL377606A1 true PL377606A1 (pl) | 2006-02-06 |
Family
ID=32682223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL377606A PL377606A1 (pl) | 2002-12-20 | 2003-12-12 | Postaci dawkowane zawierające inhibitor CETP i inhibitor reduktazy HMG-CoA |
Country Status (24)
Country | Link |
---|---|
US (1) | US7897175B2 (pl) |
EP (1) | EP1581210B1 (pl) |
JP (1) | JP2006512359A (pl) |
KR (1) | KR20050088190A (pl) |
CN (1) | CN1728995A (pl) |
AR (1) | AR042534A1 (pl) |
AT (1) | ATE389396T1 (pl) |
AU (1) | AU2003286372A1 (pl) |
BR (1) | BR0317593A (pl) |
CA (1) | CA2509688A1 (pl) |
CO (1) | CO5590898A2 (pl) |
DE (1) | DE60319877T2 (pl) |
ES (1) | ES2300628T3 (pl) |
GT (1) | GT200300295A (pl) |
IL (1) | IL169090A0 (pl) |
NL (1) | NL1025070C (pl) |
NO (1) | NO20052779L (pl) |
PE (1) | PE20040970A1 (pl) |
PL (1) | PL377606A1 (pl) |
RU (1) | RU2005119176A (pl) |
TW (1) | TW200420301A (pl) |
UY (1) | UY28134A1 (pl) |
WO (1) | WO2004056359A1 (pl) |
ZA (1) | ZA200504123B (pl) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
CA2455288A1 (en) * | 2001-06-21 | 2003-01-03 | Pfizer Products Inc. | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
CA2450748A1 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
BRPI0516772A (pt) * | 2004-10-25 | 2008-09-23 | Japan Tobacco Inc | formulação sólida com solubilidade e estabilidade melhoradas e método para produção da referida formulação |
AP2007003979A0 (en) * | 2004-11-23 | 2007-06-30 | Warner Lambert Co | 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia |
WO2006085217A2 (en) * | 2005-02-08 | 2006-08-17 | Pfizer Products Inc. | Solid adsorbates of hydrophobic drugs |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
US8828438B2 (en) | 2005-05-31 | 2014-09-09 | Bend Research, Inc. | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase |
CA2618255C (en) | 2005-08-08 | 2015-05-26 | Abbott Gmbh & Co. Kg | Itraconazole compositions with improved bioavailability |
JP2009504590A (ja) * | 2005-08-08 | 2009-02-05 | アボット ゲーエムベーハー ウント コンパニー カーゲー | 改善された生物学的利用能をもつ剤型 |
DE102005049293A1 (de) * | 2005-10-15 | 2007-04-26 | Bayer Healthcare Ag | Kombinationspräparate von Salzen oder o-Acetylsalicylsäure |
US7351853B2 (en) * | 2006-01-23 | 2008-04-01 | Albion Advanced Nutrition | Method of manufacturing a granular mineral composition |
KR100791256B1 (ko) * | 2006-03-17 | 2008-01-03 | 주식회사 대웅제약 | 약학적으로 유용하고 안정한 아토바스타틴 고체분산체 및이를 포함하는 조성물 |
US20070269503A1 (en) * | 2006-05-16 | 2007-11-22 | James Walter Burgess | Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof |
AU2007300071A1 (en) * | 2006-09-27 | 2008-04-03 | Dr. Reddy's Laboratories Ltd. | Atorvastatin pharmaceutical compositions |
WO2008065506A2 (en) * | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Pharmaceutical compositions comprising nanoparticles comprising enteric polymers and casein |
AR071706A1 (es) * | 2008-05-15 | 2010-07-07 | Otsuka Pharma Co Ltd | Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion. |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
CN103200935A (zh) | 2010-11-04 | 2013-07-10 | 霍夫曼-拉罗奇有限公司 | 包含2-甲基丙硫代酸s-[2-([[1-(2-乙基丁基)-环己基]-羰基]氨基)苯基]酯和交联羧甲基纤维素钠的组合物 |
KR101298788B1 (ko) * | 2011-03-15 | 2013-08-22 | 보령제약 주식회사 | 안정성이 개선된 복합제제 |
WO2012170417A2 (en) | 2011-06-06 | 2012-12-13 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
US8313774B1 (en) | 2012-06-26 | 2012-11-20 | Magnifica Inc. | Oral solid composition |
MA40590A (fr) * | 2014-08-28 | 2017-07-05 | Dezima Pharma B V | Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et des inhibiteurs de hmg-coa réductase |
JP2019131472A (ja) * | 2016-05-31 | 2019-08-08 | 興和株式会社 | 医薬組成物 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5180589A (en) | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
EP0680320B1 (en) | 1993-01-19 | 1999-04-14 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
DK0828495T3 (da) | 1995-06-01 | 2003-02-24 | Searle & Co | Misoprostolholdige faste stabiliserede dispersioner |
DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
ATE250929T1 (de) * | 1997-05-30 | 2003-10-15 | Osmotica Corp | Mehrlagige osmosevorrichtung |
US6235311B1 (en) | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
AU2157400A (en) * | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications |
EP1970052A2 (en) * | 1999-02-09 | 2008-09-17 | Pfizer Products Inc. | Basic drug compositions with enhanced bioavailability |
EP1027888B1 (en) * | 1999-02-10 | 2009-06-10 | Pfizer Products Inc. | Osmotic system for delivery of solid amorphous dispersions of drugs |
WO2001093860A1 (en) * | 2000-06-09 | 2001-12-13 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
US6620821B2 (en) * | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
HUP0303083A3 (en) * | 2000-08-15 | 2005-05-30 | Pfizer Prod Inc | Pharmaceutical compositions containing therapeutic combination of a cetp inhibitor and atorvastatin and their use |
US20020077348A1 (en) | 2000-11-21 | 2002-06-20 | Dean Herbert M. | Dosage unit for cardioprotection |
US20040235935A1 (en) * | 2001-06-12 | 2004-11-25 | Francis Vanderbist | Oral pharmaceutical composition containing a statin derivative |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
CA2508840A1 (en) | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
US20040132771A1 (en) | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
-
2003
- 2003-12-12 JP JP2004561902A patent/JP2006512359A/ja active Pending
- 2003-12-12 ES ES03777117T patent/ES2300628T3/es not_active Expired - Lifetime
- 2003-12-12 PL PL377606A patent/PL377606A1/pl not_active Application Discontinuation
- 2003-12-12 CN CNA2003801069589A patent/CN1728995A/zh active Pending
- 2003-12-12 AU AU2003286372A patent/AU2003286372A1/en not_active Abandoned
- 2003-12-12 KR KR1020057011269A patent/KR20050088190A/ko not_active Application Discontinuation
- 2003-12-12 BR BR0317593-6A patent/BR0317593A/pt not_active IP Right Cessation
- 2003-12-12 CA CA002509688A patent/CA2509688A1/en not_active Abandoned
- 2003-12-12 WO PCT/IB2003/006087 patent/WO2004056359A1/en active IP Right Grant
- 2003-12-12 DE DE60319877T patent/DE60319877T2/de not_active Revoked
- 2003-12-12 EP EP03777117A patent/EP1581210B1/en not_active Revoked
- 2003-12-12 RU RU2005119176/15A patent/RU2005119176A/ru not_active Application Discontinuation
- 2003-12-12 AT AT03777117T patent/ATE389396T1/de not_active IP Right Cessation
- 2003-12-18 NL NL1025070A patent/NL1025070C/nl not_active IP Right Cessation
- 2003-12-18 TW TW092135977A patent/TW200420301A/zh unknown
- 2003-12-18 US US10/739,567 patent/US7897175B2/en not_active Expired - Fee Related
- 2003-12-18 AR ARP030104713A patent/AR042534A1/es unknown
- 2003-12-18 UY UY28134A patent/UY28134A1/es not_active Application Discontinuation
- 2003-12-19 GT GT200300295A patent/GT200300295A/es unknown
-
2004
- 2004-01-05 PE PE2004000021A patent/PE20040970A1/es not_active Application Discontinuation
-
2005
- 2005-05-20 ZA ZA200504123A patent/ZA200504123B/en unknown
- 2005-06-08 NO NO20052779A patent/NO20052779L/no not_active Application Discontinuation
- 2005-06-09 IL IL169090A patent/IL169090A0/en unknown
- 2005-06-17 CO CO05059491A patent/CO5590898A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20050088190A (ko) | 2005-09-02 |
UY28134A1 (es) | 2004-07-30 |
WO2004056359A1 (en) | 2004-07-08 |
CO5590898A2 (es) | 2005-12-30 |
AU2003286372A1 (en) | 2004-07-14 |
NL1025070C (nl) | 2010-04-06 |
DE60319877T2 (de) | 2009-04-30 |
BR0317593A (pt) | 2005-11-22 |
CN1728995A (zh) | 2006-02-01 |
NO20052779D0 (no) | 2005-06-08 |
IL169090A0 (en) | 2007-07-04 |
DE60319877D1 (de) | 2008-04-30 |
JP2006512359A (ja) | 2006-04-13 |
CA2509688A1 (en) | 2004-07-08 |
ATE389396T1 (de) | 2008-04-15 |
ES2300628T3 (es) | 2008-06-16 |
RU2005119176A (ru) | 2006-01-20 |
NO20052779L (no) | 2005-08-25 |
US7897175B2 (en) | 2011-03-01 |
US20040197398A1 (en) | 2004-10-07 |
PE20040970A1 (es) | 2004-12-14 |
EP1581210A1 (en) | 2005-10-05 |
NL1025070A1 (nl) | 2004-06-22 |
AR042534A1 (es) | 2005-06-22 |
TW200420301A (en) | 2004-10-16 |
EP1581210B1 (en) | 2008-03-19 |
ZA200504123B (en) | 2006-02-22 |
GT200300295A (es) | 2004-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL169090A0 (en) | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor | |
HK1080734A1 (en) | Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor | |
PL359820A1 (pl) | Inhibitory reduktazy HMG-CoA i sposób leczenia | |
IL163929A0 (en) | Combination comprising an hmg-coa reductase inhibitor and an insulin secretor enhancer or an insulinsensitizer | |
EP1684754A4 (en) | HMG COA REDUCTASE INHIBITORS AND METHOD | |
IL166279A0 (en) | Composition comprising a cholesterol absorption inhibitor an HMG-COA reductase inhibitor and a stabilizing agent | |
GB2384947B (en) | Enabling and/or inhibiting an operation of a wireless communicatons unit | |
AP2004003189A0 (en) | Use of CETP inhibitors and optionally HMG COA reductase inhibitors and/or antihypertensive agents. | |
DE60202452D1 (de) | Pyridazinonaldose reductase inhibitoren | |
NO20026011D0 (no) | HMG-CoA-reduktase-inhibitorer og fremgangsmåte | |
GB0205527D0 (en) | Inhibitors | |
AP2005003251A0 (en) | New spirocondensed quinazolinones and their use asphosphodiesterase inhibitors. | |
GB2412372B (en) | Pyrazine-based tubulin inhibitors | |
AU2003220437A1 (en) | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | |
AU2003250172A1 (en) | Compositions comprising hmg-coa reductase inhibitor | |
PL371217A1 (pl) | Inhibitory integryny alfaVbeta6 | |
AU2003237739A1 (en) | Combination of a reflux inhibitor and an imidazopyridine for the treatment of gerd | |
EP1570847A4 (en) | PHOSPHODIESTERASE 10A HEMMER | |
AU2003256323A8 (en) | Sos1 inhibitors | |
IL154927A0 (en) | Combination of statins and sorbitol dehydrogenase inhibitors | |
AU2003267790A8 (en) | Lipase inhibitors and uses thereof | |
HK1077230A1 (en) | Medicinal composition hmg-coa reductase inhibitor | |
HUP0201597A2 (en) | Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines | |
GB0220776D0 (en) | FOXP2 and uses thereof | |
GB0001565D0 (en) | Dihydrofolate reductase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |